W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...

Just as Adverum Biotechnologies' cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy. The prize for Lilly is ixo-vec, an ...

An emerging approach that uses aqueous chlorhexidine to prevent infections after intravitreal injections to deliver drugs into the eye is as effective as the long prevailing method that uses povidone ...

New study from University of California, Irvine and University of California, Santa Barbara researchers demonstrates improved retinal function and vascular integrity, supporting further investigation ...

Objective: To investigate the relationship between the implantation position of dexamethasone intravitreal implant (DEX-I) and post-injection intraocular pressure (IOP) elevation. Methods: This ...

According to Aldeyra Therapeutics, a phase 2/3 trial of ADX-2191 in patients with retinitis pigmentosa is expected to begin in 2025. The Food and Drug Administration (FDA) has granted Fast Track ...

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal neovascularization and subretinal hemorrhage and exudation, leading to vision impairment.

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal neovascularization and subretinal hemorrhage and exudation, leading to vision impairment.

LONG BEACH, Calif. -- Prefilled syringes to treat macular degeneration caused larger and more frequent spikes in intraocular pressure (IOP) as compared with medication drawn from vials, a study of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...

NASHVILLE--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd ...